Long‐term follow‐up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B–cell non‐Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU)
Thomas E. Witzig; Patrick B. Johnston; Betsy R. LaPlant; Paul J. Kurtin; Levi D. Pederson; Dennis F. Moore Jr; Nassim H. Nabbout; Daniel A. Nikcevich; Kendrith M. Rowland; Axel Grothey
Author Information: Division of Hematology
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.